Trial Profile
A Randomised Phase II Trial Comparing the Efficacy of Single-fraction or Multi-fraction SABR (Stereotactic Ablative Body Radiotherapy) With AteZolizumab in Patients With Advanced Triple nEgative Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms AZTEC
- 18 Jul 2023 Status changed from active, no longer recruiting to completed.
- 24 May 2022 Planned End Date changed from 1 Apr 2022 to 1 Jun 2023.
- 24 May 2022 Planned primary completion date changed from 1 Oct 2021 to 1 Jun 2023.